Psoriasis

The FDA has approved a label update for a biologic used for the treatment of adult patients with moderate-to-severe plaque psoriasis

After a separate study indicated that an immunosuppressive drug used for the treatment of psoriasis reduced aortic inflammation, researchers investigated whether another common psoriasis treatment could...

Patients with psoriasis are known to have an increased risk of various cardiovascular events. In a new study, researchers evaluated various cardiovascular measures, including atherosclerotic plaque burden,...

Following the success of the reSURFACE clinical program, the US Food and Drug Administration has approved a new treatment option for adults with moderate to severe plaque psoriasis.

The results of a recent study shed light on the potential association between vitamin D and disease severity in patients with psoriasis.

Researchers at the American Academy of Dermatology 2018 Annual Meeting have indicated that cannabis may eventually be used as a topical treatment for various skin conditions.

Previous studies have indicated an association between moderate-to-severe plaque psoriasis and inflammatory bowel disease. In a new study, researchers compared the prevalence of gastrointestinal symptoms in...

No previous studies have compared the health-related quality of life in patients with moderate-to-severe psoriasis and hidradenitis suppurativa.

The FDA has approved a new indication for a drug previously approved for the treatment of adults with moderate-to-severe plaque psoriasis.

Obesity is a known risk factor for psoriasis and psoriatic arthritis. Researchers investigated whether these risks were reduced by bariatric surgery in a recent study.